4. Moretto TJ, Milton DR, Ridge TD, et al. Efﬁcacy and tolerability of exenatide mon- otherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo- controlled, parallel-group study. Clin Ther2008;30:1448 –1460 5. Aschner P, Katzeff HL, Guo H, et al. Ef ﬁcacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252 –261 6. Drucker DJ, Buse JB, Taylor K, et al. Ex- enatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferioritystudy. Lancet 2008;372:1240 –1250 7. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly re- sulted in greater improvements in glycemic control compared with exenatide twicedaily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301 –1310 8. Hommel G. A stagewise rejective multi- ple test procedure based on a modi ﬁed